11 Best GLP-1 and Weight Loss Stocks to Invest in

Page 9 of 9

1. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders: 119

Eli Lilly and Company (NYSE:LLY) revealed the topline results of the SURPASS-CVOT Phase 3 trial, which showed that Mounjaro (tirzepatide) was non-inferior to Trulicity (dulaglutide) in reducing significant cardiovascular events (MACE-3) among more than 13,000 adults with cardiovascular disease and type 2 diabetes. Mounjaro reported higher decreases in body weight (−11.43 kg vs. −4.65 kg), A1C (1.73% vs. 0.90%), and a slowed decline in kidney function by 3.54 mL/min/1.73 m² at 36 months, along with a drop in all-cause mortality by 16%.

​​Mounjaro, a GIP/GLP-1 dual receptor agonist, performed better than Trulicity, a GLP-1 agonist, in several important endpoints in the longest and most extensive tirzepatide trial to date. The 4.5-year research, which covered 30 countries, reaffirmed Mounjaro’s tolerability and safety. According to a predetermined indirect analysis, Mounjaro decreased all-cause mortality by 39% and MACE-3 by 28% when compared to a placebo. Eli Lilly and Company (NYSE:LLY) will discuss all of the findings at the 2025 EASD meeting and aims to submit regulatory applications by year’s end.

While we acknowledge the potential of LLY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LLY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stock To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9